Nephron Clinical Practice
Original Paper
Plasma Cell-Free DNA Levels in Children on Peritoneal DialysisOzkaya O.a · Bek K.a · Bedir A.b · Açıkgöz Y.a · Özdemir T.bDepartments of aPediatric Nephrology, and bBiochemistry, Ondokuz Mayıs University, School of Medicine, Samsun, Turkey
Keywords: Cell-free DNAChildrenPeritoneal dialysis |
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Subscribe
For eJournal Archive and eJournal Backfiles information please contact Karger service
Article / Publication Details
Received: February 20, 2009
Accepted: May 18, 2009
Published online: August 15, 2009
Issue release date: November 2009
Number of Print Pages: 1
Number of Figures: 2
Number of Tables: 0
eISSN: 1660-2110 (Online)
For additional information: https://www.karger.com/NEC
Abstract
Background/Aims: Plasma levels of cell-free DNA (cfDNA) are elevated in various clinical conditions including cancer, stroke, trauma, myocardial infarction, autoimmune disorders, and pregnancy-associated complications. Previously, increased cfDNA levels were reported during hemodialysis. However, there is limited data regarding cfDNA levels in peritoneal dialysis (PD) patients. The aim of this study was to investigate the levels of cfDNA in children on PD. Methods: Twenty-one children on PD (median age: 12; range: 4–18 years) and 21 healthy children (median age: 10; range: 6–16 years) were enrolled into the study. Plasma cfDNA was measured using a real-time quantitative PCR for the beta-globin gene. Results: The median concentrations of cfDNA in the plasma of PD patients and healthy controls were 2,205 genome-equivalents/ml of plasma (range: 39–5,845) and 1,033 genome-equivalents/ml of plasma (range: 254–5,116), respectively (p = 0.026). A significant positive correlation was observed between C-reactive protein levels and plasma cfDNA levels (r: 0.52, p < 0.0001). Conclusion: Our data have demonstrated for the first time that cfDNA is increased in children on PD treatment. However, the mechanism by which the levels of cfDNA is increased and the clinical significance of this finding in PD patients is unclear. Further studies are warranted to clarify the precise mechanism and clinical significance of elevated cfDNA in children on PD.
© 2009 S. Karger AG, Basel
Related Articles:
References
- Gahan PB, Swaminathan R: Circulating nucleic acids in plasma and serum. Recent developments. Ann N Y Acad Sci 2008;1137:1–6.
- Swarup V, Rajeswari MR: Circulating (cell-free) nucleic acids – a promising, non-invasive tool for early detection of several human diseases. FEBS Lett 2007;581:795–799.
-
Shao ZM, Wu J, Shen ZZ, Nguyen M: p53 mutation in plasma DNA and its prognostic value in breast cancer patients. Clin Cancer Res 2001;8:3027.
External Resources
- Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey C, Anker P: Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996;2:1033–1035.
- Lo YM, Rainer TH, Chan LY, Hjelm NM, Cocks RA: Plasma DNA as a prognostic marker in trauma patients. Clin Chem 2000;46:319–323.
- Rainer TH, Wong LK, Lam W, Yuen E, Lam NY, Metreweli C, Lo YM: Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin Chem 2003;49:562–569.
- Chang CP, Chia RH, Wu TL, Tsao KC, Sun CF, Wu JT: Elevated cell-free serum DNA detected in patients with myocardial infarction. Clin Chim Acta 2003;327:95–101.
- Koffler D, Agnello V, Winchester R, Kunkel HG:The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythematosus and other diseases. J Clin Invest 1973;52:198–204.
- Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS: Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485–487.
- Atamaniuk J, Ruzicka K, Stuhlmeier KM, Karimi A, Eigner M, Mueller MM: Cell-free plasma DNA: a marker for apoptosis during hemodialysis. Clin Chem 2006;52:523–526.
- Steinman CR, Ackad A: Appearance of circulating DNA during hemodialysis. Am J Med 1977;62:693–697.
- García Moreira V, de la Cera Martínez T, Gago González E, Prieto García B, Alvarez Menéndez FV: Increase in and clearance of cell-free plasma DNA in hemodialysis quantified by real-time PCR. Clin Chem Lab Med 2006;44:1410–1415.
- Chiu RW, Poon LL, Lau TK, Leung TN, Wong EM, Lo YM: Effects of blood processing protocols on fetal and total DNA quantification in maternal plasma. Clin Chem 2001;47:1607–1613.
- Korabecna M, Opatrna S, Wirth J, Rulcova K, Eiselt J, Sefrna F, Horinek A: Cell-free plasma DNA during peritoneal dialysis and hemodialysis and in patients with chronic kidney disease. Ann N Y Acad Sci 2008;1137:296–301.
- Rainer TH, Lam NY: Circulating nucleic acids and critical illness. Ann N Y Acad Sci 2006;1075:271–277.
- Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, Roden R, Sokoll LJ, Chan DW, Shih IeM: Increased plasma DNA integrity in cancer patients. Cancer Res 2003;63:3966–3968.
- Matsumoto Y, Shinzato T, Amano I, Takai I, Kimura Y, Morita H, Miwa M, Nakane K, Yoshikai Y, Maeda K: Relationship between susceptibility to apoptosis and Fas expression in peripheral blood T cells from uremic patients: a possible mechanism for lymphopenia in chronic renal failure. Biochem Biophys Res Commun 1995;215:98–105.
- Heidenreich S, Schmidt M, Bachmann J, Harrach B: Apoptosis of monocytes cultured from long-term hemodialysis patients. Kidney Int 1996;49:792–799.
- Cendoroglo M, Jaber BL, Balakrishnan VS, Perianayagam M, King AJ, Pereira BJ: Neutrophil apoptosis and dysfunction in uremia. J Am Soc Nephrol 1999;10:93–100.
-
Jaber BL, Cendoroglo M, Balakrishnan VS, Perianayagam MC, King AJ, Pereira BJ: Apoptosis of leukocytes: basic concepts and implications in uremia. Kidney Int 2001;78(suppl):197–205.
External Resources
- Catalán MP, Reyero A, Egido J, Ortiz A: Acceleration of neutrophil apoptosis by glucose-containing peritoneal dialysis solutions: role of caspases. J Am Soc Nephrol 2001;12:2442–2449.
- Catalán M, Santamaría B, Reyero A, Ortiz A, Egido J, Ortiz A: 3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis. Kidney Int 2005;68:1303–1311.
- Pulm J, Lordnejad MR, Grabensee B: Effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes. Kidney Int 1998;54:224–235.
- Cendoroglo M, Sundaram S, Groves C, Ucci AA, Jaber BL, Pereira BJ: Necrosis and apoptosis of polymorphonuclear cells exposed to peritoneal dialysis fluids in vitro. Kidney Int 1997;52:1626–1634.
- Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B: Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int 1990;37:116–125.
- Botezatu I, Serdyuk O, Potapova G, Shelepov V, Alechina R, Molyaka Y, Ananev V, Bazin I, Garin A, Narimanov M, Knysh V, Melkonyan H, Umansky S, Lichtenstein A: Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem 2000;46:1078–1084.
Article / Publication Details
Received: February 20, 2009
Accepted: May 18, 2009
Published online: August 15, 2009
Issue release date: November 2009
Number of Print Pages: 1
Number of Figures: 2
Number of Tables: 0
eISSN: 1660-2110 (Online)
For additional information: https://www.karger.com/NEC
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
